Arrowhead Pharmaceuticals, Inc. (BVMF:A2RR34)

Market Cap	50.15B +427.4%
Revenue (ttm)	3.24B +43,539.2%
Net Income	-1.57B
EPS	-11.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	491
Average Volume	857
Open	48.64
Previous Close	46.76
Day's Range	48.00 - 48.64
52-Week Range	9.83 - 50.32
Beta	1.29
RSI	58.92
Earnings Date	Aug 5, 2026

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 711
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A2RR34

Financial Performance

In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Financial numbers in USD